Mechanistic study of COL6A1 ‐mediated subchondral bone remodeling in osteoarthritis via the EPAC / RAP1 axis
The FASEB Journal · 2025
DOI: 10.1096/fj.202402818rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Qu Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Third Ward of Orthopaedic Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China. Hauptthemen laut MEDLINE: Osteoarthritis, Guanine Nucleotide Exchange Factors, Bone Remodeling, Collagen Type VI. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
This study aimed to identify key molecular targets that drive osteoclasts (OCs) influenced progression of osteoarthritis (OA) and to explore their mechanisms influencing OCs differentiation and OA progression. We conducted weighted gene co‐expression network analysis (WGCNA) and differential expression analysis using OA datasets from the GEO database, cross‐referencing these findings with OCs differentiation datasets, ultimately identifying COL6A1 as a hub gene. Validation results indicated that COL6A1 expression was increased during both OA progression and OCs differentiation. Immune‐related analysis indicates that the expression level of COL6A1 can influence the immune microenvironment in the subchondral bone of OA. Subsequent in vitro perturbation and rescue experiments demonstrated that COL6A1 enhances OCs differentiation and formation by activating the EPAC/RAP1 signaling axis. In vivo experiments further confirmed that COL6A1 knockdown reduced OC‐mediated subchondral bone remodeling and slowed OA progression in DMM mouse models. Additionally, the molecular docking results suggest that ingenol‐mebutate is a potential functional inhibitor of COL6A1. In summary, this study indicates that COL6A1 promotes the differentiation and formation of OCs by activating the EPAC/RAP1 signaling axis. Targeted blockade of COL6A1 can alleviate subchondral bone remodeling and OA progression in DMM model mice. Ingenol mebutate is a potential therapeutic drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third Ward of Orthopaedic Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
- Institute of Osteoarthropathy, Ningxia Key Laboratory of Clinical and Pathogenic Microbiology, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Chin…
ORCID-Profile: Qu Xu, Gangning Feng, Zhiqun Tang, Rui Wang, Penggang Ma, Jiangbo Yan, Zhihai Zhang, Long Ma, Qunhua Jin
Zitieren
APA
Xu, Q., Feng, G., Tang, Z., Wang, R., Ma, P., Yan, J., Zhang, Z., Ma, L., & Jin, Q. (2025). Mechanistic study of COL6A1 ‐mediated subchondral bone remodeling in osteoarthritis via the EPAC / RAP1 axis. The FASEB Journal. https://doi.org/10.1096/fj.202402818rr
Vancouver
Xu Q, Feng G, Tang Z, Wang R, Ma P, Yan J, et al. Mechanistic study of COL6A1 ‐mediated subchondral bone remodeling in osteoarthritis via the EPAC / RAP1 axis. The FASEB Journal. 2025. doi:10.1096/fj.202402818rr
BibTeX
@article{Xu2025,
author = {Xu, Qu and Feng, Gangning and Tang, Zhiqun and Wang, Rui and Ma, Penggang and Yan, Jiangbo and Zhang, Zhihai and Ma, Long and Jin, Qunhua},
title = {Mechanistic study of COL6A1 ‐mediated subchondral bone remodeling in osteoarthritis via the EPAC / RAP1 axis},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202402818rr}
}
EUVIMED